More preclinical studies are now needed to confirm these results and to evaluate the toxicity of this therapeutic approach, and in parallel, to study the signaling pathway controlled by CD44 during tumor recurrence with a view to developing specific inhibitors. The gene discussed is CD44; the disease is neoplasm.